Literature DB >> 6138082

Relationship between plasma concentration and effect of midazolam after oral and intravenous administration.

C Crevoisier, W H Ziegler, M Eckert, P Heizmann.   

Abstract

In a double-blind, cross-over study in six healthy volunteers, the effects of different oral doses of midazolam (10, 20 and 40 mg), or 0.15 mg kg-1 midazolam administered intravenously and of placebo were investigated. Plasma concentrations of midazolam and of its active alpha-hydroxy metabolite were measured at the same time. The effect was assessed using objective and subjective methods (reaction time, tracing test, subjects' self-assessment and investigator's subjective assessment). The respective time courses of the plasma concentration and of the effect (reaction time, number of errors in the tracing test) were almost identical. Peak plasma levels and maximum effects were attained within 30 min. In general, the effect after intravenous injection of 0.15 mg kg-1 and after an oral dose of 10 mg midazolam lasted for 2 h following administration and its duration was doubled (i.e. to 4 h) after the 20 mg oral dose. Between the logarithm of the plasma concentration and the effect, there is a sigmoidal relationship that is virtually time independent. Particularly in the first few hours after oral administration the effect is intensified by the alpha-hydroxy metabolite of midazolam which is formed by first-pass metabolism. At identical plasma concentrations of midazolam, the oral dose produced more marked effects than did the intravenous administration. Correlation of the measured effects with the total (midazolam + alpha-hydroxy midazolam) plasma concentration reveals a closer sigmoidal relationship.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138082      PMCID: PMC1428096          DOI: 10.1111/j.1365-2125.1983.tb02271.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

2.  Pharmacokinetics and bioavailability of midazolam in man.

Authors:  P Heizmann; M Eckert; W H Ziegler
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

4.  [Relationship between clinical effects and pharmacokinetics of midazolam on i.m. and i.v. application to volunteers/1st comm.: Clinical aspects (author's transl)].

Authors:  W H Ziegler; J D Thurneysen; C Crevoisier; M Eckert; R Amrein; R Dubuis
Journal:  Arzneimittelforschung       Date:  1981

5.  The pharmacokinetics of midazolam in man.

Authors:  M T Smith; M J Eadie; T O Brophy
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

6.  Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites.

Authors:  W H Ziegler; E Schalch; B Leishman; M Eckert
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

  6 in total
  29 in total

1.  Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.

Authors:  A Cleton; D Mazee; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.

Authors:  P D Knoester; D M Jonker; R T M Van Der Hoeven; T A C Vermeij; P M Edelbroek; G J Brekelmans; G J de Haan
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

3.  Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.

Authors:  J W Mandema; E Tukker; M Danhof
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

Review 4.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

5.  Hypnotics. Drug selection by means of the System of Objectified Judgement Analysis (SOJA) method.

Authors:  R Janknegt; A van der Kuy; G Declerck; C Idzikowski
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 6.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 7.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Comparative absorption kinetics of intramuscular midazolam and diazepam.

Authors:  O R Hung; J B Dyck; J Varvel; S L Shafer; D R Stanski
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

9.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

10.  Dose equivalence of midazolam and triazolam. A psychometric study based on flicker sensitivity, reaction time and digit symbol substitution test.

Authors:  H J Sostmann; H Sostmann; C Crevoisier; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.